Madrigal Pharmaceuticals
Corporate brand
UnclaimedA biopharmaceutical company focused on developing novel therapeutics for MASH, a serious liver disease.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. The company's research program led to the first FDA-approved treatment in MASH. Madrigal was founded by Rebecca Taub, M.D., and is headquartered in West Conshohocken, United States. It went public on the NASDAQ Global Market in 2016.
History
Madrigal Pharmaceuticals was founded by Rebecca Taub, M.D., who began applying her understanding of liver biology to explore therapies for MASH in the early 2000s. The company was incorporated in 2011 and initiated a Phase 1 trial. In 2016, Madrigal went public on the NASDAQ Global Market as MDGL and commenced a Phase 2 clinical trial. The company's research program led to the first FDA-approved treatment in MASH.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/madrigal-pharmaceuticals-united-states · Editorial policy · How profiles are compiled